Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review

Janna de Boer*, Erik Boot, Lissa van Gils, Therese van Amelsvoort, Janneke Zinkstok

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Web of Science)

Abstract

The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic medication, we carried out a literature review. A systematic search strategy was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Publications describing adverse effects of antipsychotic medication in patients with 22q11.2DS were included in the review and assessed for their methodological quality. A total of 11 publications reporting on eight trials, cross-sectional or cohort studies, and 30 case reports were included. The most commonly reported adverse effects can be classified into the following categories: movement disorders, weight gain, seizures, cardiac side effects, and cytopenias. Many of these symptoms are manifestations of 22q11.2DS, also in the absence of antipsychotic medication. Based on the reviewed literature, a causal relation between antipsychotic medication and the reported adverse effects could not be established in the majority of cases. Randomized clinical trials are needed to make firm conclusions regarding risk of adverse effects of antipsychotics in patients with 22q11.2DS.

Original languageEnglish
Pages (from-to)2292-2306
Number of pages15
JournalAmerican Journal of Medical Genetics Part A
Volume179
Issue number11
Early online date13 Aug 2019
DOIs
Publication statusPublished - Nov 2019

Keywords

  • 22q11
  • 2 deletion syndrome
  • adverse effects
  • antipsychotic medication
  • systematic review
  • CARDIO-FACIAL SYNDROME
  • TREATMENT-RESISTANT PSYCHOSIS
  • ONSET PARKINSON DISEASE
  • RISK-FACTORS
  • SCHIZOPHRENIA
  • CLOZAPINE
  • ADULTS
  • NEUTROPENIA
  • ADOLESCENT
  • CHILDHOOD

Cite this